Preclinical characteristics of the irreversible pan- her kinase inhibitor neratinib compared with lapatinib: Implications for the treatment of HER2- positive and HER2-mutated breast cancer

Preclinical characteristics of the irreversible pan- her kinase inhibitor neratinib compared with lapatinib: Implications for the treatment of HER2- positive and HER2-mutated breast cancer

10.3390/cancers11060737

Saved in:
Bibliographic Details
Main Authors: Collins, D.M., Conlon, N.T., Kannan, S., Verma, C.S., Eli, L.D., Lalani, A.S., Crown, J.
Other Authors: BIOLOGICAL SCIENCES
Format: Review
Published: MDPI AG 2021
Subjects:
Breast cancer
HER2
Lapatinib
Neratinib
Tyrosine kinase inhibitors
Online Access:https://scholarbank.nus.edu.sg/handle/10635/210771
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: National University of Singapore
Description
Summary:10.3390/cancers11060737

Similar Items